These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 25638806)

  • 1. Growth in children and adolescents with juvenile idiopathic arthritis over 2 years of treatment with etanercept: results from the British Society for Paediatric and Adolescent Rheumatology Etanercept Cohort Study.
    Kearsley-Fleet L; Hyrich KL; Davies R; Lunt M; Southwood TR;
    Rheumatology (Oxford); 2015 Jul; 54(7):1279-85. PubMed ID: 25638806
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Medically Significant Infections Are Increased in Patients With Juvenile Idiopathic Arthritis Treated With Etanercept: Results From the British Society for Paediatric and Adolescent Rheumatology Etanercept Cohort Study.
    Davies R; Southwood TR; Kearsley-Fleet L; Lunt M; Hyrich KL;
    Arthritis Rheumatol; 2015 Sep; 67(9):2487-94. PubMed ID: 25989609
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Growth patterns in early juvenile idiopathic arthritis: Results from the Childhood Arthritis Prospective Study (CAPS).
    McErlane F; Carrasco R; Kearsley-Fleet L; Baildam EM; Wedderburn LR; Foster HE; Ioannou Y; Chieng SEA; Davidson JE; Thomson W; Hyrich KL
    Semin Arthritis Rheum; 2018 Aug; 48(1):53-60. PubMed ID: 29217290
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Factors associated with improvement in disease activity following initiation of etanercept in children and young people with Juvenile Idiopathic Arthritis: results from the British Society for Paediatric and Adolescent Rheumatology Etanercept Cohort Study.
    Kearsley-Fleet L; Davies R; Lunt M; Southwood TR; Hyrich KL
    Rheumatology (Oxford); 2016 May; 55(5):840-7. PubMed ID: 26721878
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Factors associated with treatment response to etanercept in juvenile idiopathic arthritis.
    Otten MH; Prince FH; Armbrust W; ten Cate R; Hoppenreijs EP; Twilt M; Koopman-Keemink Y; Gorter SL; Dolman KM; Swart JF; van den Berg JM; Wulffraat NM; van Rossum MA; van Suijlekom-Smit LW
    JAMA; 2011 Dec; 306(21):2340-7. PubMed ID: 22056397
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bone status over 1 yr of etanercept treatment in juvenile idiopathic arthritis.
    Simonini G; Giani T; Stagi S; de Martino M; Falcini F
    Rheumatology (Oxford); 2005 Jun; 44(6):777-80. PubMed ID: 15741191
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of anti-TNF treatment on growth in severe juvenile idiopathic arthritis.
    Tynjälä P; Lahdenne P; Vähäsalo P; Kautiainen H; Honkanen V
    Ann Rheum Dis; 2006 Aug; 65(8):1044-9. PubMed ID: 16449314
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improvement in health-related quality of life for children with juvenile idiopathic arthritis after start of treatment with etanercept.
    Klotsche J; Minden K; Thon A; Ganser G; Urban A; Horneff G
    Arthritis Care Res (Hoboken); 2014 Feb; 66(2):253-62. PubMed ID: 23983081
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of open-label etanercept on extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis and psoriatic arthritis: part 1 (week 12) of the CLIPPER study.
    Horneff G; Burgos-Vargas R; Constantin T; Foeldvari I; Vojinovic J; Chasnyk VG; Dehoorne J; Panaviene V; Susic G; Stanevica V; Kobusinska K; Zuber Z; Mouy R; Rumba-Rozenfelde I; Breda L; Dolezalova P; Job-Deslandre C; Wulffraat N; Alvarez D; Zang C; Wajdula J; Woodworth D; Vlahos B; Martini A; Ruperto N;
    Ann Rheum Dis; 2014 Jun; 73(6):1114-22. PubMed ID: 23696632
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Etanercept treatment improves longitudinal growth in prepubertal children with juvenile idiopathic arthritis.
    Vojvodich PF; Hansen JB; Andersson U; Sävendahl L; Hagelberg S
    J Rheumatol; 2007 Dec; 34(12):2481-5. PubMed ID: 18050366
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Duration of etanercept treatment and reasons for discontinuation in a cohort of juvenile idiopathic arthritis patients.
    Southwood TR; Foster HE; Davidson JE; Hyrich KL; Cotter CB; Wedderburn LR; Hull RG; Venning HE; Rahman JK; Cummins CL;
    Rheumatology (Oxford); 2011 Jan; 50(1):189-95. PubMed ID: 21047801
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improvement of functional ability in children with juvenile idiopathic arthritis by treatment with etanercept.
    Halbig M; Horneff G
    Rheumatol Int; 2009 Dec; 30(2):229-38. PubMed ID: 19449011
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Etanercept improves lipid profile and oxidative stress measures in patients with juvenile idiopathic arthritis.
    De Sanctis S; Marcovecchio ML; Gaspari S; Del Torto M; Mohn A; Chiarelli F; Breda L
    J Rheumatol; 2013 Jun; 40(6):943-8. PubMed ID: 23547210
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Achievement of clinical remission in patients with juvenile idiopathic arthritis under a 2-10-year Etanercept exposure.
    Trachana M; Pratsidou-Gertsi P; Badouraki M; Haidich AB; Pardalos G
    Clin Rheumatol; 2013 Aug; 32(8):1191-7. PubMed ID: 23604548
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and efficacy of long-term etanercept in the treatment of methotrexate-refractory polyarticular-course juvenile idiopathic arthritis in Japan.
    Mori M; Takei S; Imagawa T; Imanaka H; Nerome Y; Higuchi R; Kawano Y; Yokota S; Sugiyama N; Yuasa H; Fletcher T; Wajdula JS
    Mod Rheumatol; 2012 Sep; 22(5):720-6. PubMed ID: 22212889
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Major improvements in health-related quality of life during the use of etanercept in patients with previously refractory juvenile idiopathic arthritis.
    Prince FH; Geerdink LM; Borsboom GJ; Twilt M; van Rossum MA; Hoppenreijs EP; Cate RT; Koopman-Keemink Y; van Santen-Hoeufft M; Raat H; van Suijlekom-Smit LW
    Ann Rheum Dis; 2010 Jan; 69(1):138-42. PubMed ID: 19581280
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of etanercept in patients with the enthesitis-related arthritis category of juvenile idiopathic arthritis: results from a phase III randomized, double-blind study.
    Horneff G; Foeldvari I; Minden K; Trauzeddel R; Kümmerle-Deschner JB; Tenbrock K; Ganser G; Huppertz HI
    Arthritis Rheumatol; 2015 May; 67(8):2240-9. PubMed ID: 25891010
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term safety and effectiveness of etanercept in children with selected categories of juvenile idiopathic arthritis.
    Giannini EH; Ilowite NT; Lovell DJ; Wallace CA; Rabinovich CE; Reiff A; Higgins G; Gottlieb B; Singer NG; Chon Y; Lin SL; Baumgartner SW;
    Arthritis Rheum; 2009 Sep; 60(9):2794-804. PubMed ID: 19714630
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Etanercept concentration and immunogenicity do not influence the response to Etanercept in patients with juvenile idiopathic arthritis.
    Bader-Meunier B; Krzysiek R; Lemelle I; Pajot C; Carbasse A; Poignant S; Melki I; Quartier P; Choupeaux L; Henry E; Treluyer JM; Belot A; Hacein-Bey-Abina S; Urien S
    Semin Arthritis Rheum; 2019 Jun; 48(6):1014-1018. PubMed ID: 30396593
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-world comparison of the effects of etanercept and adalimumab on well-being in non-systemic juvenile idiopathic arthritis: a propensity score matched cohort study.
    van Straalen JW; de Roock S; Giancane G; Consolaro A; Rygg M; Nordal EB; Rubio-Pérez N; Jelusic M; De Inocencio J; Vojinovic J; Wulffraat NM; Bruijning-Verhagen PCJ; Ruperto N; Swart JF;
    Pediatr Rheumatol Online J; 2022 Nov; 20(1):96. PubMed ID: 36376976
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.